Zions Bancorporation’s NovoCure NVCR Stock Holding History

Zions Bancorporation’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-44	Closed	-$1.83K	–	911
2023 Q2	$1.83K	Buy	44 +7	+19%	+$435	﹤0.01%	824
2023 Q1	$2.23K	Hold	37	–	–	﹤0.01%	814
2022 Q4	$2.71K	Hold	37	–	–	﹤0.01%	927
2022 Q3	$3K	Sell	37 -25	-40%	-$1.95K	﹤0.01%	840
2022 Q2	$4K	Sell	62 -38	-38%	-$2.86K	﹤0.01%	894
2022 Q1	$8K	Buy	100 +79	+376%	+$5.82K	﹤0.01%	865
2021 Q4	$2K	Sell	21 -19	-48%	-$1.91K	﹤0.01%	937
2021 Q3	$5K	Buy	40 +8	+25%	+$1.21K	﹤0.01%	824
2021 Q2	$7K	Buy	32 +15	+88%	+$2.92K	﹤0.01%	790
2021 Q1	$2K	Buy	+17	New	+$2.69K	﹤0.01%	889
2019 Q1	–	Sell	-321	Closed	-$11K	–	966
2018 Q4	$11K	Buy	+321	New	+$11.7K	0.01%	324

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Zions Bancorporation's NVCR Position: Q3 2023 in Review

Zions Bancorporation sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 44 shares — an estimated $1.83K sold.

Zions Bancorporation first reported a position in NVCR in Q4 2018 and held it in 11 quarters. The position peaked at $11K in Q4 2018. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Zions Bancorporation reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Zions Bancorporation sold 44 NovoCure shares in Q3 2023, an estimated $1.83K.
Zions Bancorporation first reported a position in NovoCure in Q4 2018 and held it in 11 quarters.
Zions Bancorporation's NovoCure position peaked at $11K in Q4 2018.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Zions Bancorporation's 13F filing for Q3 2023, filed 7 Nov 2023.